ClinicalTrials.gg
RecruitingNCT02670707Updated Sep 11, 2025

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

A Phase 3 interventional study of Cytarabine and Vinblastine/prednisone in Langerhans Cell Histiocytosis, sponsored by Baylor College of Medicine. Recruiting at 11 sites in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Baylor College of Medicine · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2016; still recruiting 10 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Histiocytosis, Langerhans-Cell with a site in United States — 8 open to participants now, 25 under way, 2 of them phase 3. Histiocytosis, Langerhans-Cell · United States.

Planned enrollment
7th of 40
124 · median 21
Started
2016
with 2 others
Phase 3
Only one
of the 47
Primary completion
2027-01
later than 15 of 24 live
Registered
22nd of 47
by date
Lead sponsor
2 of 47
Baylor College of Medicine

Among the 47 studies in Histiocytosis, Langerhans-Cell with a site in United States, this one is the 7th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2016, is the only one in phase 3, reaches primary completion later than 15 of the 24 other live ones, and was the 22nd registered.

Histiocytosis, Langerhans-Cell

81 studies on the registry are indexed under Histiocytosis, Langerhans-Cell; 23 are open to participants now.

Browse Histiocytosis, Langerhans-Cell studies →

Open to participants now

8 of the 47 studies in Histiocytosis, Langerhans-Cell with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Histiocytosis, Langerhans-Cell with a site in United States, or all of them as a file.
02

Study summary

Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body. Langerhans cell histiocytosis (LCH) is a cancer that begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make the LCH cells grow and multiply quickly. This causes LCH cells to build up in certain parts of the body, where they can damage tissue or form lesions.

For most patients with LCH, standard-of-care vinblastine/prednisone are used as front-line therapy while cytarabine therapy has been used as therapy for patients who develop recurrence. No alternate treatment strategy has been developed for frontline therapy in LCH.

The purpose of this research study is to compare previously used vinblastine/prednisone to single therapy with cytarabine for LCH. We will evaluate the utility of an imaging study called a positron emission tomography (PET) scan to more accurately assess areas of LCH involvement not otherwise seen in other imaging studies as well as response to therapy. We also want to identify if genetic and other biomarkers (special proteins in patient's blood and in patient's cancer) relate to the response of patients LCH to study treatment.

Read the detailed description

To be eligible to participate in this study, patients physician must have determined that they have LCH which is not treatable by surgical intervention or observation alone. If patient chooses to participate in this study, they will be assigned randomly (like flipping a coin) to one of two LCH chemotherapy treatment groups. A computer will randomly determine if they will begin to receive vinblastine/prednisone treatment or cytarabine treatment. Patient will have an equal chance (50%) to receive vinblastine/prednisone or to receive cytarabine. Neither the patient nor their doctor will be able to choose the group assignment, but the patient and their study doctor will know which treatment they are receiving.

The patient will need to have the following tests, exams, or procedures. Most of these are part of regular cancer care and may be done even if the patient does not want to join this study. Some of them may not need to be repeated if they have had them done recently. The patient's doctor will tell them which ones they need to repeat.

  • History and Physical
  • Blood tests
  • Urine tests
  • Biopsy to confirm diagnosis
  • Bone Marrow biopsy/aspirate (if patient is less than 2 years old or for any patient clinical concern for bone marrow disease)*
  • Lumbar puncture for spinal fluid tests (if patient has disease in pituitary gland or brain)

    • The bone marrow sample procedure is as follows: The skin above the hipbone will be made numb. This area will then be sterilized and a small incision will be made. A bone marrow needle will be inserted into the hipbone and bone marrow will be withdrawn. Patient will sign a separate consent that explains this procedure in more detail.

We will also do x-rays and scans of the inside of the body. These scans may include chest and bone x-rays, ultrasound, computerized tomography (CT), magnetic resonance imaging (MRI) and/or positron emission tomography (PET). The specific tests depend on age, sites of LCH and other clinical factors. An ultrasound is a sound wave machine that uses a computer to make pictures of the tissues of the body. A CT is an x-ray machine that uses a computer to make pictures of the organs of the body. An MRI is a scan which uses a magnetic machine to make pictures of the inside of the body. A PET scan is an x-ray technique that uses a sugar solution that you drink to see activity inside the body. The PET and CT scans will look at where the LCH is in the body.

If tests show that the patient can participate in this study and they choose to participate, treatment will begin based on randomization to either the cytarabine ("experimental") arm or the vinblastine/prednisone ("standard") arm as described below.

Patient will have a history and physical and blood tests before each cycle. The cancer drugs will be given to the patient intravenously (IV). An IV is a tube placed inside a vein to give medicine to the patient. If at anytime during the study the cancer gets worse, the patient will be taken off the study treatment.

  1. Cytarabine ("experimental") arm

    Initial therapy I (Weeks 1-6)

    • Cytarabine for five consecutive days. This five-day cycle will be repeated every 21 days for a total of two cycles.

    Patient will have scans to see how the LCH responded to the treatment during week 6. Patients who have Complete Response (CR), Partial Response (PR), or Stable Disease (SD) at the end of Initial Therapy I, will proceed to Initial Therapy II (Weeks 7-12). Patients who have PR or SD at the end of Initial Therapy I will require reassessment again at the end of Initial Therapy II. Patients who have CR at the end of Initial Therapy I do not require disease reassessment again until Continuation Week 24.

    Initial therapy II (Weeks 7-12)

    • Cytarabine for five consecutive days. This five-day cycle will be repeated every 21 days for a total of two cycles.

    Patient will have scans to see how the LCH responded to the treatment during week 12 (unless they had no active disease at week 6). If the patient had LCH in their bone marrow (BM) at the beginning of the study, they will have another BM biopsy. If the cancer is stable and does not respond to therapy by Week 12, the patient will be taken off the study treatment. If the patient has no evidence of active disease at this time they will proceed to Continuation therapy.

    Continuation therapy (Weeks 13-52)

    • Cytarabine for five consecutive days. This five-day cycle will be repeated every 28 days for 10 additional cycles to complete one year of therapy

    Patient will have scans to see how the LCH responded to the treatment at Week 24 and at the end of therapy. If the patient had LCH in their bone marrow (BM) at the beginning of the study, they will have another BM biopsy.

  2. Vinblastine/prednisone ("standard") arm

Initial therapy I (Weeks 1-6)

  • Prednisone given by mouth two times a day daily on days 1-28 AND
  • Vinblastine will be given IV (into a vein) one day a week for 6 weeks

Patient will have scans to see how the LCH responded to the treatment after week 6. If the patient had LCH in their bone marrow (BM) at the beginning of the study, they will have another BM biopsy. If the disease is completely gone by Week 6, patient will proceed to Continuation therapy. If the disease is only partly gone or unchanged patient will receive additional therapy with Initial therapy II.

Patient will have scans to see how the LCH responded to the treatment during Week 12 and if they had LCH in their bone marrow (BM) at the beginning of the study, they will have another BM biopsy.

Initial therapy II (Weeks 7-12, given only if the patient does not have evidence of active disease by Week 6)

  • Prednisone by mouth on the first three days of each week during weeks 7-12 AND
  • Vinblastine IV weekly during weeks 7-12

If the disease is gone or better after this additional therapy Continuation therapy will begin.

Continuation therapy

  • Prednisone by mouth twice daily day on days 1-5 every 3 weeks AND
  • Vinblastine IV once every 3 weeks
  • 6-Mercaptopurine by mouth daily NOTE: Only high risk patients will receive 6-Mercaptopurine

Patient will have scans to see how the LCH responded to the treatment at Week 24 and at the end of therapy. If the patient had LCH in their bone marrow (BM) at the beginning of the study, they will have another BM biopsy.

STUDY FOLLOW-UP: Patient will be in this study for 5 years after completion of their therapy. The doctors will exam the patient at 1 month, 3 months, 6 months, 9 months, 12 months, then at 18 and 24 months, then yearly until 5 years after the patient is taken off treatment. At these visits the patient may have routine blood tests, scans, and the biology tests.

03

Conditions studied

  • Langerhans Cell Histiocytosis

Keywords

  • vinblastine
  • prednisone
  • cytarabine
  • Langerhans Cell Histiocytosis (LCH)
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must have -confirmed diagnosis of Langerhans cell histiocytosis.
  2. Patient must be between 0-21 years of age.
  3. Patient must have a performance score ≥ 50% or Lansky performance score ≥ 50%.

Exclusion criteria

Exclusion Criteria:

  1. Patient may not have received any prior systemic cytotoxic or other chemotherapies for LCH or any other malignant disorder prior to the initiation of protocol therapy on TXCH LCH0115 with the exception of:

    pretreatment: Systemic glucocorticosteroids (prednisone, methylprednisone, dexamethasone, etc.) for less than or equal to 120 hours (5 days) in the 7 days prior to initiating protocol therapy or for less than or equal to 336 hours (14 days) in the 28 days before the initiation of protocol therapy does not affect eligibility. The dose of steroid previously given does not affect eligibility. Patients who have only received surgical or radiation therapy, intralesional injection of steroids, inhalational steroids, systemic mineralocorticoids (hydrocortisone), or topical steroids may also be enrolled.

  2. Patient may not have disease limited to a single skin or bone site, with the following exceptions:

    • Central Nervous System (CNS) risk lesions/special site disease: patients with single bone sites that are CNS-risk (sphenoid, mastoid, orbital, zygomatic, ethmoid, maxillary, or temporal bones, the cranial fossa, pituitary gland or neurodegenerative disease) or are "special sites" (odontoid peg, vertebral lesion with intraspinal soft tissue extension) require systemic therapy as standard of care and thus are eligible for the study.
    • Functionally critical lesions: A single lesion not described above which may cause "functionally critical anatomic abnormality" wherein attempts at local therapy (such as surgical curettage or radiation) would cause unacceptable morbidity. These patients may be enrolled with written approval of the Coordinating Center PI or Vice-Chair and documentation of the rationale justifying systemic therapy.
    • Asynchronous multisite LCH presentation: A patient may also have any single site of disease involvement at the time of enrollment if they previously had at least one other site of LCH disease in the past (which may have been treated with local therapy/surgery as described), as long as no systemic therapy was previously given per protocol guidelines.
  3. Patient may not have severe renal disease (creatinine greater than 3 times normal for age OR \< 50 ml/m2/1.73m\^2).
  4. Patient may not have severe hepatic disease (direct greater than 3 mg/dl OR (AST) greater than 500 IU/L), unless hepatic injury is due to LCH.
  5. Female patients may not be pregnant or breastfeeding.
  6. Patients of not willing to use an adequate method of for the duration of the study.
  7. Patients who are positive may not be enrolled.

NOTE: Patients excluded for laboratory abnormalities or performance score only may be enrolled on the study with written approval from the Coordinating Center PI or Vice-Chair.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Cytarabine ("experimental") arm

    On this arm, patients will receive single therapy with cytarabine.

    Drug: Cytarabine

  • Active comparator
    Vinblastine/prednisone ("standard") arm

    On this arm, patients will receive standard-of-care therapy with vinblastine and prednisone.

    Drug: Vinblastine/prednisone

Interventions

  • Cytarabine 100 mg/m\^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.

    Also known as: cytosine arabinoside (ara-C)

  • DrugVinblastine/prednisone

    Vinblastine/Prednisone +/- 6-mercaptopurine based on risk category. Patients with high-risk organ involvement (liver, spleen, hematopoeitic system) will receive 6-mercaptopurine during Continuation Therapy as this is the current standard of care treatment. Vinblastine 6 mg/m\^2/dose IV push weekly for patients ≥ 12 months of age. Vinblastine will be dosed at 3 mg/m\^2/dose for patients under 6 months of age, and dosed at 4.5 mg/m\^2/dose for patients 6 months of age to 11.99 months of age. Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day

    Also known as: Velban/Deltasone

06

What researchers measure

Primary outcomes

  1. Time to determine 1-year event-free survival (EFS) of patients treated with cytarabine monotherapy for LCH, compared directly with that of standard-of-care vinblastine/prednisone (Events include progression of LCH, relapse, or death).

    A Kaplan-Meier curve will be used to compare event-free survival between treatment groups. Curves will be compared using the log-rank statistic. Patients will be followed for up to 5 years after one year of therapy. Patients who have not had the event by the 5-year mark will be censored observations. Patients who are lost to follow-up without having an event will be censored at the time of last contact. Statistical significance will be assessed at the 0.05 level. A Cox proportional hazards model will also be used to estimate the Hazards Rate for combined events in the Cytarabine group versus standard therapy. A multiple regression model will also be used to estimate the adjusted HRs for genotype and baseline risk of death (high vs. low).

    Time frame: up to 60 months

Secondary outcomes

  1. Durable responses with 2-year and 5-year EFS and OS of the patients treated with cytarabine versus vinblastine/prednisone for LCH.

    Overall disease response at each timepoint will be assigned based on the lesion or organ system with worst response. For disease response not defined by the criteria included in the protocol, guidelines established in the RECIST criteria will be used.

    Time frame: 2-years and 5-years post treatment

  2. Number of toxicities (including psychosis, hypertension, neuropathy, fever, headache) in the patients treated with cytarabine versus vinblastine/prednisone for LCH.

    Toxicity will be graded by the NCI Common Toxicity Criteria Version 5.0.

    Time frame: up to 60 months after completion of therapy

  3. Rate at which patients achieve non-active disease on cytarabine versus vinblastine/prednisone therapy.

    RECIST criteria will be used for assessing disease response

    Time frame: up to 60 months after completion of therapy

  4. Time to eradication of BRAF-V600E cells or other LCH-defining mutation

    This will be quantified by quantitative real-time PCR.

    Time frame: within 6-24 weeks of therapy initiation

  5. Number of patients who have 18-FDG PET/CT positivity in identifying high-risk organ (liver, spleen, or bone marrow) involvement and correlation of PET/CT response with presence of disease activity as well as presence of circulating cells with BRAF-V600E.

    For disease response not defined by the criteria included in the protocol, guidelines established in the RECIST criteria will be used.

    Time frame: up to 60 months after completion of therapy

  6. RECIST criteria and terminology in conjunction with metabolic PET imaging (where applicable) to assess disease response to therapy.

    This trial will utilize RECIST criteria for assessing disease response, which uses standard oncology response criteria terminology. Using RECIST terminology, we define response criteria for organs that may not have measurable lesions (i.e. bone marrow) but are clearly critical sites of disease. In addition, definitions of response in terms of metabolic activity from PET scans will also be prospectively analyzed based on prior retrospective radiologic reviews.

    Time frame: up to 60 months after completion of therapy

  7. Number of risk factors for and time to development of diabetes insipidus and neurodegenerative disease.

    Evaluation of CNS+ site involvement at start of therapy, somatic BRAFV600E mutation status and measurable peripheral/marrow levels, ethnicity, age at onset, and extent of disease in predicting risk of neurodegenerative disease and/or pituitary involvement.

    Time frame: up to 60 months after completion of therapy

  8. Storage of serial samples

    To store serial samples (viable WBCs, plasma, tumor, bone marrow, cerebrospinal fluid) for future correlative biology studies.

    Time frame: up to 60 months after completion of therapy

07

Study locations

10 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2016 (actual). Primary completion is estimated for Jan 2027, 130 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2016
First posted
Feb 2, 2016
StartActual
Mar 7, 2016
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2029
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02670707
Responsible party
Olive Eckstein (Assistant Professor, Baylor College of Medicine) — Principal investigator
First posted
Feb 2, 2016
Start date
Mar 7, 2016
Primary completion
Jan 2027 (estimated)
Completion
Jan 2029 (estimated)
Last update
Sep 11, 2025

Study contacts

Olive Eckstein, MD
Contact
Eckstein@bcm.edu
832-822-4242
Carl E. Allen, MD, PhD
Contact
ceallen@txch.org
832-826-0860
Olive Eckstein, MD
study chair · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytarabine

Start the discussion